research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy
Anti-EGFR therapy can cause skin issues, but FGF7 treatment might help.
research Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.
research 129 Targeted inhibition of EGFR reduces anti-microbial defense mechanisms at the hair canal
Inhibiting EGFR weakens skin's defense against bacteria.
research Molecular Docking Studies and ADME Prediction of Novel Isatin Analogs with Potent Anti-EGFR Activity
Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
research LAM/TSC Cell Migration to Uterus in an Experimental Model of Lymphangioleiomyomatosis. Regulation by Anti-Epidermal Growth Factor Receptor Antibody and Rapamycin
Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
research Skin toxicity of anti‐cancer therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research 308 Epidermal keratinocytes regulate bacterial immune responses and host defense through EGFR
EGFR inhibitors cause skin issues and hair loss by weakening skin defenses, suggesting antibiotics and targeted treatments can help.
research MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research New Plant Extracts Exert Complementary Anti‐Hair Loss Properties in Human In Vitro and Ex Vivo Models
The plant extracts may help treat hair loss by promoting hair growth and reducing DHT levels.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
Cetuximab can cause unusual hair growth and hair loss.
research Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline
Doxycycline can effectively treat hair loss caused by EGFR inhibitors.
research Lupeol: an updated review utilizing AI-assisted predictive tools for enhanced therapeutic insights into lupeol’s potential for alopecia management
Lupeol shows promise for hair growth but needs better absorption and safety testing.
research Network pharmacology, molecular docking, and dynamics reveal the mechanisms of Hejie Shengfa Decoction against alopecia areata
Hejie Shengfa Decoction may help treat alopecia areata by promoting hair growth and reducing inflammation, but more safety studies are needed.
research EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
research 1030 EGFR protects the upper hair follicle from staphylococcus driven folliculitis
EGFR helps protect hair follicles from bacterial infections.
research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.
research 1338 Epidermal growth factor receptor protects from immune privilege collapse and scarring hair follicle destruction
Blocking EGFR can lead to hair loss due to inflammation and stem cell damage.
research Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
Iressa often causes skin issues like acne and dryness in lung cancer patients.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Characteristics of pregnancy with Systemic Lupus Erythematosus (SLE) in Dr. Mohammad Hoesin Hospital, Palembang
Most pregnancies with SLE resulted in intrauterine growth restriction (IUGR).
research Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin
EGF receptor is crucial for skin health and its inhibitors can cause skin rashes.
research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
research Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of ‘Dermatology for Cancer Patients’
Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.
research Drug Repurposing Patent Applications April–June 2021
Drug repurposing shows promise for treating many medical conditions.